Page 2 of 2
What do these findings mean?
The researchers concluded that GSK3359609 and tremelimumab in combination was similar in terms of
safety to each medicine individually.
Since the results of Part 1 did not show enough evidence that the study medicine combination improved
the outcome for patients with cancer, Part 2 of the study was not started.
We would like to thank the participants who contributed to this study. The
results of this study will help answer scientific questions about cancer treatment.
The content for this document was finalized by GSK on 20 December 2021. The
information in this summary does not include additional information available
after this date.